Merck announces Canadian approval for GRASTEK tablets Merck announced the regulatory approval and launch of GRASTEK sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Merck previously announced that the U.S. Food and Drug Administration had accepted for review Biologics License Applications for GRASTEK and for its investigational ragweed sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in 1H14. Merck has partnered with ALK-Abello to develop its sublingual allergy immunotherapy tablets for Timothy grass pollen, ragweed pollen and house dust mite-induced allergic rhinitis in North America.